The Cav3.1 T-type calcium channel is required for neointimal formation in response to vascular injury in mice

Cardiovascular Research

Volumn 96, Issue 3, 2012, Pages 533-542

  Tzeng, Bing Hsiean ^a,b,c   Chen, Yen Hui ^c   Huang, Ching Hui ^a,c   Lin, Shin Shiou ^c,d   Lee, Kuan Rong ^d   Chen, Chien Chang ^a,c  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^d NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

Calcium channel blocker; Cell proliferation; Neointimal formation; T type calcium channels

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL T TYPE; CALMODULIN; CALP1; CYCLIN E; MESSENGER RNA; NNC 55 0396; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAROTID ARTERY; CAROTID ARTERY INJURY; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; G1 PHASE CELL CYCLE CHECKPOINT; HISTOPATHOLOGY; MALE; MOUSE; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RESTENOSIS; RNA INTERFERENCE; SMOOTH MUSCLE FIBER; UPREGULATION; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

ANIMALS; BENZIMIDAZOLES; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, T-TYPE; CALMODULIN; CAROTID ARTERIES; CAROTID ARTERY INJURIES; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; CELLS, CULTURED; CYCLIN E; CYCLOPROPANES; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NAPHTHALENES; NEOINTIMA; OLIGOPEPTIDES; RNA INTERFERENCE; RNA, MESSENGER; TIME FACTORS; TRANSFECTION; VASCULAR SYSTEM INJURIES;

EID: 84869464401     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs257     Document Type: Article

References (53)

1. Orford JL, Selwyn AP, Ganz P, Popma JJ, Rogers C. The comparative pathobiology of atherosclerosis and restenosis. Am J Cardiol 2000;86:6H-11H.
2. Davis C, Fischer J, Ley K, Sarembock IJ. The role of inflammation in vascular injury and repair. J Thromb Haemost 2003;1:1699-1709.
3. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005;115:3378-3384. (Pubitemid 43121822)
4. Holmes DR Jr, Savage M, LaBlanche JM, Grip L, Serruys PW, Fitzgerald P et al. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2002;106:1243-1250. (Pubitemid 34988643)
5. Serruys PW, Foley DP, Pieper M, Kleijne JA, de Feyter PJ. The TRAPIST Study. A mul-ticentre randomized placebo controlled clinical trial of trapidil for prevention of restenosis after coronary stenting, measured by 3-D intravascular ultrasound. Eur Heart J 2001;22:1938-1947. (Pubitemid 33054674)
6. Emanuelsson H, Beatt KJ, Bagger JP, Balcon R, Heikkila J, Piessens J et al. Long-term effects of angiopeptin treatment in coronary angioplasty. Reduction of clinical events but not angiographic restenosis. European Angiopeptin Study Group. Circulation 1995;91:1689-1696.
7. von Essen R, Ostermaier R, Grube E, Mäurer W, Tebbe U, Erbel R et al. Effects of octreotide treatment on restenosis After coronary angioplasty: results of the VERAS study. Circulation 1997;96:1482-1487. (Pubitemid 27375340)
8. 2+ entry: a way to control cell proliferation. Curr Med Chem 2004;11:1533-1543. (Pubitemid 38735795)
9. 2+ storage in cultured vascular smooth muscle cells. Circ Res 1997;80:617-626. (Pubitemid 27181344)
10. Bean BP. Classes of calcium channels in vertebrate cells. Annu Rev Physiol 1989;51:367-384. (Pubitemid 19088326)
11. Hermsmeyer K. Differences of calcium channels in vascular muscle in hypertension. Am J Hypertens 1991;4:412S-415S.
12. Braun AP. Multi-tasking at the protein level: L-type calcium channels function as iono-tropic and metabotropic activators of smooth muscle contraction. Channels (Austin) 2011;5:459-460.
13. 2+ currents in rat aortic smooth muscle cells in primary culture. Circ Res 1996;79:14-19.
14. Perez-Reyes E. Molecular physiology of low-voltage-activated T-type calcium channels. Physiol Rev 2003;83:117-161. (Pubitemid 36459879)
15. 2+ channels in vascular smooth muscle: multiple functions. Cell calcium 2006;40:221-230. (Pubitemid 43942303)
16. Rodman DM, Reese K, Harral J, Fouty B, Wu S, West J et al. Low-voltage-activated (T-type) calcium channels control proliferation of human pulmonary artery myocytes. Circ Res 2005;96:864-872. (Pubitemid 40604970)
17. 2+ channels promote oxygenation-induced closure of the rat ductus arteriosus not only by vasoconstriction but also by neointima formation. J Biol Chem 2009;284:24025-24034.
18. v3.1 T-type calcium channels in IGF-I-stimulated pulmonary artery smooth muscle cells. Am J Physiol Cell Physiol 2011; 300:C517-C525.
19. Hillegass WB, Ohman EM, Leimberger JD, Califf RM. A meta-analysis of randomized trials of calcium antagonists to reduce restenosis after coronary angioplasty. Am J Cardiol 1994;73:835-839. (Pubitemid 24158299)
20. Jorgensen B, Simonsen S, Endresen K, Forfang K, Vatne K, Hansen J et al. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES). J Am Coll Cardiol 2000;35:592-599. (Pubitemid 30170253)
21. Bestehorn HP, Neumann FJ, Buttner HJ, Betz P, Sturzenhofecker P, von Hodenberg E et al. Evaluation of the effect of oral verapamil on clinical outcome and angiographic restenosis after percutaneous coronary intervention: the randomized, double-blind, placebo-controlled, multicenter Verapamil Slow-Release for Prevention of Cardiovascular Events After Angioplasty (VESPA) Trial. J Am Coll Cardiol 2004;43:2160-2165. (Pubitemid 38765106)
22. Dens J, Desmet W, Piessens J. An updated meta-analysis of calcium-channel blockers in the prevention of restenosis after coronary angioplasty. Am Heart J 2003;145:404-408. (Pubitemid 36390484)
23. 1G) expressed in Xenopus oocytes. J Cardiovasc Pharmacol 2005;45:241-246. (Pubitemid 40328146)
24. Bergson P, Lipkind G, Lee SP, Duban ME, Hanck DA. Verapamil block of T-type calcium channels. Mol Pharmacol 2011;79:411-419.
25. Schmitt R, Clozel JP, Iberg N, Buhler FR. Mibefradil prevents neointima formation after vascular injury in rats. Possible role of the blockade of the T-type voltage-operated calcium channel. Arterioscler Thromb Vasc Biol 1995;15:1161-1165.
26. 2+ channels. Neuron 2001;31:35-45. (Pubitemid 32757087)
27. 2+ channels. Science 2003; 302:1416-1418. (Pubitemid 37452187)
28. Lynn Ray J, Leach R, Herbert J-M, Benson M. Isolation of vascular smooth muscle cells from a single murine aorta. Methods in Cell Science 2001;23:185-188. (Pubitemid 34863290)
29. Sedding DG, Braun-Dullaeus RC. In vitro cultivation of vascular smooth muscle cells. In: Dhein S, Mohr FW, Delmar M, eds. Practical methods in cardiovascular research. Heidelberg, Germany: Springer-Verlag, 2005:630-639.
30. Miller AM, McPhaden AR, Wadsworth RM, Wainwright CL. Inhibition by leukocyte depletion of neointima formation after balloon angioplasty in a rabbit model of restenosis. Cardiovasc Res 2001;49:838-850. (Pubitemid 32178388)
31. Matter CM, Ma L, von Lukowicz T, Meier P, Lohmann C, Zhang D et al. Increased balloon-induced inflammation, proliferation, and neointima formation in apolipopro-tein E (ApoE) knockout mice. Stroke 2006;37:2625-2632. (Pubitemid 44454689)
32. 1G T-type calcium channels. Circ Res 2006;98:1422-1430. (Pubitemid 43948067)
33. 1-S phase protein kinase. Science 1992;257:1958-1961.
34. 1 cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol 2000;12:676-684.
35. Tanner FC, Greutert H, Barandier C, Frischknecht K, Luscher TF. Different cell cycle regulation of vascular smooth muscle in genetic hypertension. Hypertension 2003;42:184-188. (Pubitemid 36944594)
36. 1/S transitions in vascular smooth muscle cells. Circ Res 2006;98:1273-1281. (Pubitemid 43948082)
37. Hui S, Choi J, Zaidi S, Momen A, Steinbach SK, Sadi A-M et al. Peptide-mediated disruption of calmodulin-cyclin E interactions inhibits proliferation of vascular smooth muscle cells and neointima formation. Circ Res 2011;108:1053-1062.
38. Villain M, Jackson PL, Manion MK, Dong W-J, Su Z, Fassina G et al. De novo design of peptides targeted to the EF hands of calmodulin. J Biol Chem 2000;275:2676-2685. (Pubitemid 30082036)
39. Braunstein TH, Inoue R, Cribbs L, Oike M, Ito Y, Holstein-Rathlou NH et al. The role of L-and T-type calcium channels in local and remote calcium responses in rat mes-enteric terminal arterioles. J Vasc Res 2009;46:138-151.
40. Figueroa XF, Chen C-C, Campbell KP, Damon DN, Day KH, Ramos S et al. Are voltage-dependent ion channels involved in the endothelial cell control of vasomotor tone? Am J Physiol Heart Circ Physiol 2007;293:H1371-H1383. (Pubitemid 47367179)
41. Ca channel diversity and smooth muscle cell function. Circ Res 1999;85:e33-e43.
42. Miguel-Velado E, Moreno-Dominguez A, Colinas O, Cidad P, Heras M, Perez-Garcia MT et al. Contribution of Kv channels to phenotypic remodeling of human uterine artery smooth muscle cells. Circ Res 2005;97:1280-1287.
43. V1.3 channel blockers. Cardiovasc Res 2011;89:282-289.
44. Kohler R, Wulff H, Eichler I, Kneifel M, Neumann D, Knorr A et al. Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation 2003;108:1119-1125. (Pubitemid 37071524)
45. Lory P, Bidaud I, Chemin J. T-type calcium channels in differentiation and proliferation. Cell Calcium 2006;40:135-146. (Pubitemid 43964483)
46. 2+ currents in cultured newborn rat ventricular myocytes. J Mol Cell Cardiol 1998;30:1095-1103. (Pubitemid 28327778)
47. Berridge MJ. Calcium signalling and cell proliferation. Bioessays 1995;17:491-500.
48. Santella L. The role of calcium in the cell cycle: facts and hypotheses. Biochem Biophys Res Commun 1998;244:317-324. (Pubitemid 28414080)
49. Kahl CR, Means AR. Regulation of cell cycle progression by calcium/calmodulin-dependent pathways. Endocr Rev 2003;24:719-736. (Pubitemid 38067696)
50. 2+ channel in the proliferating smooth muscle cells of rat aorta. J Cell Biochem 2002;87:242-251.
51. 2+ channel and dystrophin expression after balloon injury in rat aortic cells. Cardiovasc Res 2001;49:177-188.
52. Huang L, Keyser BM, Tagmose TM, Hansen JB, Taylor JT, Zhuang H et al. NNC55-0396 [(1S, 2S)-2-(2-(N-[(3-benzimidazol-2-yl)propyl]-N-methylamino)ethyl)- 6-fluoro-1, 2, 3, 4-tetrahydro-1-isopropyl-2-naphtyl cyclopropanecarboxylate dihydrochloride]: a new selective inhibitor of T-type calcium channels. J Pharmacol Exp Ther 2004;309:193-199. (Pubitemid 38393130)
53. Bui PH, Quesada A, Handforth A, Hankinson O. The mibefradil derivative NNC55-0396, a specific T-type calcium channel antagonist, exhibits less CYP3A4 inhibition than mibefradil. Drug Metab Dispos 2008;36:1291-1299. (Pubitemid 351929313)